APA

Runnebaum I. B., Wang-Gohrke S., Vesprini D., Kreienberg R., Lynch H., Moslehi R., Ghadirian P., Weber B., Godwin A. K., Risch H., Garber J., Lerman C., Olopade O. I., Foulkes W. D., Karlan B., Warner E., Rosen B., Rebbeck T., Tonin P., Dubé M. P., Kieback D. G. & Narod S. A. (20011226). Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. : Pharmacogenetics.

Chicago

Runnebaum I B, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin A K, Risch H, Garber J, Lerman C, Olopade O I, Foulkes W D, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M P, Kieback D G and Narod S A. 20011226. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. : Pharmacogenetics.

Harvard

Runnebaum I. B., Wang-Gohrke S., Vesprini D., Kreienberg R., Lynch H., Moslehi R., Ghadirian P., Weber B., Godwin A. K., Risch H., Garber J., Lerman C., Olopade O. I., Foulkes W. D., Karlan B., Warner E., Rosen B., Rebbeck T., Tonin P., Dubé M. P., Kieback D. G. and Narod S. A. (20011226). Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. : Pharmacogenetics.

MLA

Runnebaum I B, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin A K, Risch H, Garber J, Lerman C, Olopade O I, Foulkes W D, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dubé M P, Kieback D G and Narod S A. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. : Pharmacogenetics. 20011226.